Skip to content

Study · Randomized controlled trial · n = 1,139 · 2024

5 results

Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.

Wang J, Yang J, Jiang W, Liu W, Shen Z, Gao Z, Chang B

Diabetes, obesity & metabolism27 Aug 2024Cited by 8 (Europe PMC)

PMID39188242 (opens in a new tab)DOI10.1111/dom.15860 (opens in a new tab)PepBankPUB-39188242
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes without diabetic kidney disease at baseline, semaglutide reduced the odds of developing diabetic kidney disease versus placebo.

    In plain wordsIn adults with type 2 diabetes, semaglutide lowered the chance of developing diabetic kidney disease compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseDevelopment of diabetic kidney disease, total population
    Study

    n = 1,139

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.5/1.0 mgAs given in this study (human).

    Measurements

    odds ratio
    0.56 ratio
    total population

    Source sentences

    Summary
    Semaglutide significantly reduced the risk of developing DKD in both the total [odds ratio 0.56 (95% confidence interval: 0.42; 0.74; p < 0.0001)]
    1 context sentence
    Summary · context
    Participants with type 2 diabetes from the randomized, double-blind, placebo-controlled SUSTAIN 6 trial without DKD at baseline who received 0.5/1.0 mg semaglutide or placebo were grouped by baseline DKD risk, calculated using a validated model.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high risk of diabetic kidney disease, semaglutide reduced the odds of developing the disease versus placebo.

    In plain wordsIn adults with type 2 diabetes at high kidney risk, semaglutide lowered the chance of developing diabetic kidney disease compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseDevelopment of diabetic kidney disease, high DKD risk population
    Study

    n = 952

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.5/1.0 mgAs given in this study (human).

    Measurements

    odds ratio
    0.51 ratio
    high DKD risk population

    Source sentences

    Summary
    high DKD risk population [odds ratio 0.51 (95% confidence interval: 0.38; 0.69; p < 0.0001)]
    1 context sentence
    Summary · context
    Participants with type 2 diabetes from the randomized, double-blind, placebo-controlled SUSTAIN 6 trial without DKD at baseline who received 0.5/1.0 mg semaglutide or placebo were grouped by baseline DKD risk, calculated using a validated model.
  3. 03HumanRandomized controlled trialMechanism

    The beneficial effects of semaglutide on diabetic kidney disease were largely driven by changes in the urinary albumin/creatinine ratio.

    In plain wordsThe kidney benefit of semaglutide was largely explained by changes in urine albumin levels.

    Peptide
    Semaglutide
    Outcome
    Not applicableRole of UACR change in the benefit on diabetic kidney disease
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.5/1.0 mgAs given in this study (human).

    Source sentences

    Summary
    The beneficial effects of semaglutide were largely driven by UACR changes.
    1 context sentence
    Summary · context
    Participants with type 2 diabetes from the randomized, double-blind, placebo-controlled SUSTAIN 6 trial without DKD at baseline who received 0.5/1.0 mg semaglutide or placebo were grouped by baseline DKD risk, calculated using a validated model.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, semaglutide significantly delayed the development of diabetic kidney disease versus placebo.

    In plain wordsIn adults with type 2 diabetes, semaglutide delayed the start of diabetic kidney disease compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseTime to diabetic kidney disease development
    Study

    n = 1,139

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.5/1.0 mgAs given in this study (human).

    Source sentences

    Summary
    and significantly delayed DKD development versus placebo
    1 context sentence
    Summary · context
    Participants with type 2 diabetes from the randomized, double-blind, placebo-controlled SUSTAIN 6 trial without DKD at baseline who received 0.5/1.0 mg semaglutide or placebo were grouped by baseline DKD risk, calculated using a validated model.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes at high risk of diabetic kidney disease, the number needed to treat with semaglutide was 7.

    In plain wordsIn people with type 2 diabetes at high kidney risk, about 7 people needed semaglutide for one to avoid diabetic kidney disease.

    Peptide
    Semaglutide
    Outcome
    Not applicableNumber needed to treat to prevent diabetic kidney disease, high risk population
    Study

    n = 952

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.5/1.0 mgAs given in this study (human).

    Measurements

    number needed to treat
    7 participants
    high DKD risk population

    Source sentences

    Summary
    The number needed to treat for semaglutide in the high DKD risk population was 7.
    1 context sentence
    Summary · context
    Participants with type 2 diabetes from the randomized, double-blind, placebo-controlled SUSTAIN 6 trial without DKD at baseline who received 0.5/1.0 mg semaglutide or placebo were grouped by baseline DKD risk, calculated using a validated model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.